Jump to Main Content

Corporate Support

Where science and business join for impact

The American Society of Hematology (ASH) is the world's largest professional society concerned with the causes and treatments of blood disorders. The Society provides multiple opportunities for corporations, foundations, and other organizations to engage with leading hematologists around the world and demonstrate support that advances the field of hematology. There are a variety of opportunities for industry to support the Society's educational programs and annual meeting materials and services. As a benefit for supporting ASH initiatives, priority points are awarded. These points determine your ranking and placement on the exhibit floor at future ASH annual meetings.

Business Development, Your Innovation Partners

Business Development works to foster meaningful relationships with all those who make curing blood-based disorders their priority. As the conduit for these partnerships, our team amplifies the specific strengths each interest group offers to create opportunities for engagement that highlights each stakeholder.

Just as blood is integral to all bodily functions, ASH is integral to facilitating dynamic progress in the fight to treat and eventually cure all hematologic disorders.

Joint Initiatives Overview

Joint Initiatives Overview
Learn more
  • The premier event in malignant and non-malignant hematology, the ASH annual meeting highlights the highest-caliber science and the most important areas of clinical progress in hematology.


  • The ASH Research Collaborative (ASH RC) is a non-profit organization that was established by the American Society of Hematology (ASH) in 2018 to foster collaborative partnerships to accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases. The foundation of the ASH RC is its Data Hub, a technology platform that facilitates the exchange of information by aggregating research-grade data on hematologic diseases. The ASH RC Sickle Cell Disease Clinical Trials Network optimizes the conduct of clinical trials research in SCD and leverages the Data Hub to collect key information and identify gaps to advance SCD research and treatment.


  • ASH provides many awards and programs to support hematologists in all stages of their careers and to honor those who have helped to advance the field of hematology.


  • The Corporate Friends Program is an opportunity for true partnership and open dialogue with the American Society of Hematology and offers an exclusive opportunity to form strategic connections while fostering excellence within the field. The program offers pioneering companies an opportunity to invest in the field of hematology on an annual basis.


Thank you to our Corporate Friends for fostering excellence in the hematology space:

Premier Circle

 Regeneron logo Partner Spotlight: "Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases."

Partner Circle

Kite-Gilead company logo      Takeda   Vertex

Advocate Circle

Abbvie company logo  Agios company logo  Amgen  Astrazeneva company logo  Bayer logo    Daiichi Sankyo company logo  GenentechV2  GSK company logo  Janssen company logo  LegendV2  Lilly Oncology company logo  MerckV3  Pharmacyclics company logo  Sanofi Genzyme company logo  Taiho Oncology company logo


Insider Circle

AstellasV2  Atata Bio company logo  Bluebird company logo  Gamida Cell company logo  Kadmon  OmerosV2  OrcaBioV2  PreludeV2  RigelV2  TGv2